These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 23835115

  • 1. A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy.
    Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, Schipper M, Shilkrut M, Sandler HM, Morgan TM, Palapattu GS, Hamstra DA, Feng FY.
    Radiat Oncol; 2013 Jul 08; 8():170. PubMed ID: 23835115
    [Abstract] [Full Text] [Related]

  • 2. Less advanced disease at initiation of salvage androgen deprivation therapy is associated with decreased mortality following biochemical failure post-salvage radiation therapy.
    Foster CC, Jackson WC, Foster BC, Johnson SB, Feng FY, Hamstra DA.
    Radiat Oncol; 2014 Nov 26; 9():245. PubMed ID: 25424123
    [Abstract] [Full Text] [Related]

  • 3. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
    Johnson SB, Hamstra DA, Jackson WC, Zhou J, Foster B, Foster C, Song Y, Li D, Palapattu GS, Kunju L, Mehra R, Sandler H, Feng FY.
    Int J Radiat Oncol Biol Phys; 2013 Oct 01; 87(2):275-81. PubMed ID: 23886418
    [Abstract] [Full Text] [Related]

  • 4. The interval to biochemical failure is prognostic for metastasis, prostate cancer-specific mortality, and overall mortality after salvage radiation therapy for prostate cancer.
    Johnson S, Jackson W, Li D, Song Y, Foster C, Foster B, Zhou J, Vainshtein J, Feng F, Hamstra D.
    Int J Radiat Oncol Biol Phys; 2013 Jul 01; 86(3):554-61. PubMed ID: 23561650
    [Abstract] [Full Text] [Related]

  • 5. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy.
    Jackson W, Hamstra DA, Johnson S, Zhou J, Foster B, Foster C, Li D, Song Y, Palapattu GS, Kunju LP, Mehra R, Feng FY.
    Cancer; 2013 Sep 15; 119(18):3287-94. PubMed ID: 23821578
    [Abstract] [Full Text] [Related]

  • 6. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
    Lohm G, Neumann K, Budach V, Wiegel T, Hoecht S, Gollrad J.
    Strahlenther Onkol; 2018 Apr 15; 194(4):325-332. PubMed ID: 29255924
    [Abstract] [Full Text] [Related]

  • 7. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy.
    Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML.
    J Urol; 2004 Dec 15; 172(6 Pt 1):2244-8. PubMed ID: 15538240
    [Abstract] [Full Text] [Related]

  • 8. Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy.
    Jackson WC, Johnson SB, Foster B, Foster C, Li D, Song Y, Vainshtein J, Zhou J, Hamstra DA, Feng FY.
    Pract Radiat Oncol; 2014 Dec 15; 4(2):99-107. PubMed ID: 24890350
    [Abstract] [Full Text] [Related]

  • 9. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
    Howard LE, Moreira DM, De Hoedt A, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Terris MK, Freedland SJ.
    BJU Int; 2017 Nov 15; 120(5B):E80-E86. PubMed ID: 28371163
    [Abstract] [Full Text] [Related]

  • 10. Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure.
    Jackson WC, Suresh K, Tumati V, Dess RT, Soni PD, Zhao SG, Zumsteg ZS, Hannan R, Hollenbeck BK, George A, Kaffenberger SD, Salami SS, Hearn JWD, Morgan TM, Mehra R, Schipper M, Feng FY, Desai NB, Spratt DE.
    Eur Urol Oncol; 2018 Sep 15; 1(4):276-282. PubMed ID: 31100248
    [Abstract] [Full Text] [Related]

  • 11. Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy.
    Campbell SR, Tom MC, Agrawal S, Efstathiou JA, Michalski JM, Abramowitz MC, Pollack A, Spratt DE, Hearn JWD, Stephans KL, Gao T, Li J, Tendulkar RD.
    Eur Urol Oncol; 2022 Jun 15; 5(3):304-313. PubMed ID: 34016556
    [Abstract] [Full Text] [Related]

  • 12. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC, Schipper MJ, Johnson SB, Foster C, Li D, Sandler HM, Palapattu GS, Hamstra DA, Feng FY.
    Eur Urol; 2016 Jan 15; 69(1):50-7. PubMed ID: 26004800
    [Abstract] [Full Text] [Related]

  • 13. Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy.
    Jackson WC, Johnson SB, Feng FY, Hamstra DA.
    Am J Clin Oncol; 2015 Aug 15; 38(4):367-72. PubMed ID: 23822986
    [Abstract] [Full Text] [Related]

  • 14. A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy.
    Johnson S, Jackson W, Speers C, Feng F, Hamstra D.
    Pract Radiat Oncol; 2014 Aug 15; 4(6):422-9. PubMed ID: 25407865
    [Abstract] [Full Text] [Related]

  • 15. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G, Fossati N, Karnes RJ, Boorjian SA, Colicchia M, Bossi A, Seisen T, Cozzarini C, Di Muzio N, Noris Chiorda B, Zaffuto E, Wiegel T, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Briganti A.
    Eur Urol; 2018 Apr 15; 73(4):512-518. PubMed ID: 29229176
    [Abstract] [Full Text] [Related]

  • 16. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM.
    JAMA; 2004 Mar 17; 291(11):1325-32. PubMed ID: 15026399
    [Abstract] [Full Text] [Related]

  • 17. Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer.
    Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R, Buskirk SJ.
    J Clin Oncol; 2016 Nov 10; 34(32):3864-3871. PubMed ID: 27480153
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.